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Objective: We assessed associations between mental health and osteoarthritis (OA) pain.
Methods: Two hundred and sixty-six subjects with hip and/or knee OA from the Longitudinal Exami-
nation of Arthritis Pain (LEAP) study were interviewed weekly for 12 weeks, measuring Western Ontario
and McMaster University Osteoarthritis Index (WOMAC) pain subscale and 5-item Mental Health
Inventory (MHI-5).
We examined associations between MHI-5 and its change, divided into quartiles, to WOMAC pain and its
change (occurring 1 week later) using linear regression, adjusting for age, sex, body mass index (BMI),
medication use. Generalized estimating equations were used to account for repeated measurements
correlation. We also assessed the relation of MHI-5 to the risk of pain ﬂare using conditional logistic
regression in a case-crossover study.
Results: Seventy-ﬁve men and 191 women were included. Mean age was 65.0, mean BMI 31.5. 82% had
knee as their primary site. The mean WOMAC score was 2.93 in the quartile with the highest MHI-5 as
compared with a mean WOMAC of 4.57 in the quartile with the lowest MHI-5 (P for trend across
quartiles <0.001). In the case-crossover analysis (91 subjects), periods with the worst MHI-5 quartile had
2.1 times the odds of a pain ﬂare the subsequent week as compared to periods with the best MHI-5
quartile (P< 0.001).
Conclusion: We demonstrate an association between worsened measures of mental health and OA pain
and risk of pain ﬂares. General mental health is a modiﬁable component of health and may represent
a new avenue for prevention of OA pain ﬂares.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is a common and debilitating disease,
affecting approximately 12% of those between 25 and 74 years of
age1, with almost 27 million adults in the US having clinical OA of
any joint2. This condition is associated with the vast majority of hip
and knee replacement surgeries and costs to society approach $15
billion per year in the US3.
For the majority of patients, pain in OA is episodic in nature. In
the Boston Osteoarthritis Study, 39% of those with radiographic
knee OA as well as pain on most days during any month in the
previous year had Western Ontario and McMaster Universityto: Barton Wise, Center for
al Center, 4800 2nd Avenue,
B.L. Wise).
s Research Society International. POsteoarthritis Index (WOMAC) pain scores that varied from little or
no pain to severe pain measured at three different time points over
3 years4. Further, pain intensity levels appear to vary within an
individual over both long periods as well as short periods5, ascribed
by patients variously to such factors as the weather, activity levels,
and medication use. There has been very little work done on
characterizing or describing short-term variations in pain level in
OA6, and the origins of pain in those with radiographic OA are not
well understood.
Pain itself is a complicated condition with a multitude of
components and pitfalls in measurement. The experience of pain is
generated or modiﬁed by nociception, neuropathic symptoms,
psychological and personality factors, genetic inﬂuences, past
painful experiences, comorbid conditions, and expectations related
to future pain7e12. Furthermore, measurement of pain is made
difﬁcult by a variety of only partially understood variables,
including subjects’ desire to please interviewers, high levels ofublished by Elsevier Ltd. All rights reserved.
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which dimension of pain is being measured by questions which do
not deﬁne frequency or periodicity of pain, and idiosyncratic
subject reporting styles. We have tried to eliminate some of the
between-subject problems in pain measurement by employing
a case-crossover analysis where case and control periods are
compared within a single subject.
Depression is also a common condition, has a prevalence of 16%
among elderly persons14,15, and has an impact on disability levels
comparable to other important diseases such as heart disease and
hypertension16. Psychological well-being has been signiﬁcantly
associated with disability in patients with OA17, and anxiety has
been found to be associated with knee pain in women18e20.
Modiﬁcation of depression has also been demonstrated to affect
arthritis pain levels21. There is no longitudinal study to date that has
examined ﬂuctuations in OA pain and their relation to changes in
general mental health.
The Longitudinal Examination of Arthritis Pain (LEAP) Study
investigated the relationship between self-rated pain ﬂuctuations
on a weekly basis and health outcomes including healthcare
resource use in adults treated for OA of the hip and/or knee22. We
used detailed information on mental health factors from these
weekly telephone interviews to examine the role of these factors in
ﬂuctuations of OA pain.
Materials and methods
A detailed description of the LEAP study has been published
elsewhere22. In brief, patients in the LEAP study were enrolled from
primary care as well as rheumatology practices across the United
States, with clinical diagnoses of hip or knee OA as assessed by their
own physicians. The LEAP study recruited patients by identifying
sites across the US with high numbers of OA patients. Posters were
displayed at the practices, and both practices and patients were
paid for recruitment and for participation. The subjects participated
in telephone interviews at intervals of approximately 1 week for up
to 12 weeks, during which they responded to questions about their
OA pain, psychological state, as well as a variety of other questions.
Medication use was collected by recording the number of days of
the previous week subjects had used either prescription or over-
the-counter medications to treat their pain.
Pain assessment
The outcome measure was the WOMAC pain subscale score
(0e10 scale). This scale represents worse pain at the higher end of
the scale, and was assessed by the question “Thinking about the
pain you felt in your <signal joint> because of your OA during the
last week. Please rate your pain on a scale of 0 (no pain) to 10
(extreme pain). How much pain do you have. Walking on a ﬂat
surface? Going up or down stairs? At night while lying in bed?
Sitting or lying? Standing upright?” The total score out of 50 was
normalized to a 0e10 scale for this analysis. The WOMAC was
measured at baseline and at weekly intervals, and in each case
a weekly average was obtained.
Mental health status assessment
The Mental Health Inventory-5 (MHI-5) was collected weekly in
the LEAP study. TheMHI-5measures general mental health23,24 and
assesses general mood or affect and positive well-being. It has also
been found valid for use in screening for mood disorders25. We
have reported raw scores in this paper (scale 5e30) and higher
scores indicate better mental health while lower scores indicate
worse mental health. Questions in the MHI-5 take the form of“During the past week, how much of the time were you a happy
person?” with answers in a 6 point Likert scale ranging from “all of
the time” to “none of the time”. The MHI-5 is a validated23 measure
of general mental health.
Statistical analysis
We excluded data from the analysis where the time interval
between two consecutive interviews was greater than 8 days in
order to understand the short-term relation betweenmental health
and pain. We also performed similar sub-analyses limited to either
shorter or longer time frames. Analyses were performed using SAS
statistical software, version 9.1 (SAS Institute, Inc.).
We examined associations between MHI-5 and its change to
WOMAC pain occurring 1 week later. We divided baseline MHI-5
and change from baseline to the value 1 week prior to the WOMAC
score under question into quartiles. For the MHI-5 there is no
generally agreed-upon or clinically validated cutpoint for a case of
common mental disorder. Various studies have used different
methodologies in British, German and Dutch populations to arrive
at cutpoints that vary from 60 to 76 on a normalized scale in a non-
HIV population24e26. We took the cutpoint for high prevalence of
mental health problems established by Hoeymans at 72 (or 23
points on the raw scale we use) as our cutpoint, and the ﬁrst
quartile in our study corresponds to MHI-5 values which fall below
this number. Thus, our analyses reﬂected four quartiles, the ﬁrst of
which comprised those MHI-5 values representing a population
with a high prevalence of mental health problems and the other
three representing three ordinal categories within a population of
subjects withMHI-5 values that are associated with low prevalence
of mental health problems.
In a multiple linear regression model we adjusted for age, sex,
bodymass index (BMI), and prescription and over-the-counter pain
medication use (deﬁned as whether the subject used prescription/
over-the-counter medication to treat pain during the previous
week, and if so, how many days each type was used). The depen-
dent variable was WOMAC pain and the independent variables
were quartiles of baseline MHI-5 score and change of MHI-5 score.
We used generalized estimating equations to account for correlated
data of repeated measurements within a subject.
We also conducted a case-crossover study to assess the relation
of general mental health to the risk of pain ﬂare 1 week later, using
a conditional logistic regression model. Speciﬁcally, we used each
weekly time point for each subject as the unit of analysis. We
deﬁned a “pain ﬂare” (or “case period”) as an interview where the
subject reported a WOMAC score in the highest 30% of all WOMAC
scores. We deﬁned a “control period” as an interview where the
subject reported a WOMAC score in the lowest 70% of all WOMAC
scores. Only subjects who had at least one case period and at least
one control period were included in this analysis.
Results
Three hundred and three subjects were screened in the LEAP
study, 288 were enrolled, nine subjects had no pain information
collected, and seven had only one visit with pain information
recorded. A further six subjects had greater than 8 days duration
between all visits, and these subjects were not included in the
analysis. Restricting the analyses to visits where the prior visit was
8 days or less distant eliminated 14% of the total visits and allowed
for maintenance of close proximity between putative predictors
and the WOMAC pain outcome. Also, a small number of subjects
(23) had individual visits that were apparently ﬁlled out with
reference to the pain in a different joint than their “signal joint”;
these visits were eliminated from the analyses.
Table II
Relation of MHI-5 and its change to pain intensity, adjusted for age, sex, BMI, and
medication use (linear regression model)
MHI-5 N observations Adjusted mean WOMAC pain
Baseline MHI-5 values
28e30 53 2.93
26e27 67 3.54
23e25 75 3.86
13e22 68 4.57
P for trend <0.001
Change of MHI-5
3e14 (improved) 448 3.53
1e2 517 3.59
0e0 556 3.71
(13)e(1) (worsened) 526 4.06
P for trend <0.001
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ysis group, all of whom carried a clinical diagnosis of OA of the hip
or knee or both, as ascertained by the original LEAP investigators.
67% of the subjects were recruited in rheumatology clinics and 33%
from general practice clinics. Of these subjects, 75 were men and
191 women, with a mean age of 65.0 [standard deviation (SD)
8.5] and mean BMI of 31.5 (SD 7.4) (see Table I). 82% of the
subjects had OA with the knee deﬁned as their primary site, while
18% deﬁned the hip as their primary site. OA in the signal joint was
conﬁrmed by radiograph in 80% of the subjects, while 20% did not
have radiographs available. The range of WOMAC scores was wide
and varied from 0.2 to 9.6, with a mean for the entire group of 3.8
(2.2). Mean MHI-5 was 25.1 (4.0). As described by Hutchings
et al.22, the majority of participants completed the majority of
repeated measurements, with the mean number of follow-ups
completed being 10.7 out of a possible 12 and 82% of participants
completing 10 or more interviews.Generalized estimating equations results
As shown in Table II and Fig.1, better baseline mental health was
associated with less pain as compared with worse baseline mental
health (adjusted mean WOMAC score 2.93 for the highest quartile
of MHI-5 as compared with 4.57 for the lowest quartile; P for trend
<0.001). Change of MHI-5 from baseline values was also associated
with change in WOMAC pain (Table II and Fig. 2). The greatest
improvement from baseline in mental health was associated with
better WOMAC scores as compared with the quartile with the
greatest worsening in mental health from baseline, with an
adjustedmeanWOMAC score 3.53 for the highestMHI-5 quartile as
compared with 4.06 for the lowest quartile (P for trend<0.001).We
found similar results in the same analyses limited to time frames
longer or shorter than 8 days (data not shown).Case-crossover results
Ninety-one subjects, who were the only subjects out of the
overall 266 who had both at least one case period and at least one
control period, were included in the case-crossover analysis. The
demographic characteristics of these subjects were similar to the
overall group (Table I). The WOMAC range for control periods was
0.2e4.9 and for case periods it was 5.0e9.6, with a mean WOMAC
score of 4.5 (1.8), and mean MHI-5 of 24.7 (4.0).
General mental health was associated with the risk of pain ﬂare.
As shown in Table III, when subjects had theworstMHI-5 scores the
odds of a pain ﬂare the subsequent week were 2.11 times higher
than when the same subjects were in periods with the best MHI-5
scores (P< 0.001).Table I
Subject characteristics
Characteristic Subjects
(n¼ 266)
Case-crossover subjects
(n¼ 91)
Age, years [mean (SD)] 65 (8.5) 65 (8.8)
Female [n (%)] 191 (71) 72 (79)
BMI, kg/m2 [mean (SD)] 31.5 (7.4) 31.4 (8.8)
Race e Non-Hispanic White 89% 89%
Race e African-American 6% 8%
Race e other 5% 3%
Knee as primary site [n (%)] 216 (82) 71 (78)
Hip as primary site [n (%)] 50 (18) 20 (22)
WOMAC range 0.2e9.6 0.2e4.9 (control periods)
5.0e9.6 (case periods)
WOMAC [mean (SD)] 3.8 (2.2) 4.5 (1.8)
MHI-5 [mean (SD)] 25.1 (4.0) 24.7 (4.0)Discussion
In summary, worse baseline mental health is associated with
worse OA knee pain in a cross-sectional analysis. Furthermore,
improvement in mental health from baseline is associated with
reduction in pain of OA. Lastly, the risk of a pain ﬂare is increased by
worsened mental health in the week prior to the ﬂare. These three
basic ﬁndings support a strong association and possibly predictive
relation between mental health and OA pain.
The rationale for examining the mental health factors and their
relation to pain in OA is multifold. First, it is clear that the etiology
of OA pain is not well understood, and that both peripheral and
central neuronal abnormalities of function may play a part27. Given
the importance of the central nervous system in understanding
pain, and the known relation between depression or other
components of mental health and intrinsic neuronal function,
psychological factors become prime suspects as mediators of the
experience of pain.
Second, pain in a variety of other conditions has been found
to be associated with psychological state, and treatment with
anti-depressants has been found to alleviate pain. Tricyclic anti-
depressants have been demonstrated in small trials to be effective
at reducing pain in rheumatoid arthritis patients28e30, but have not
achieved widespread use for treatment of that disease, given the
development of disease-modifying drugs for that condition; at
present there are no available disease-modifying treatments for OA.
Three recent meta-analyses of anti-depressant treatment for
ﬁbromyalgia have all supported the likelihood of a modest effect on
pain with tricyclics31e33, but duloxetine has demonstrated0
1
2
3
4
5
6
0 1 2 3 4
Quartiles of MHI-5
W
O
M
A
C
 
P
a
i
n
Fig. 1. Baseline MHI-5 in quartiles with mean WOMAC pain, adjusted for age, sex, BMI,
and medication use. P for trend <0.001. The ﬁrst quartile is those with the best mental
health, while the fourth quartile represents those with the worst mental health. Error
bars represent 95% conﬁdence intervals.
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Fig. 2. Change in MHI-5 with mean change in WOMAC pain, adjusted for age, sex, BMI,
and medication use. P for trend <0.001. Error bars represent 95% conﬁdence intervals.
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pain in randomized, controlled clinical trials34,35.
Lastly, there has been some preliminary evidence that treatment
of depression, a powerful factor in mental health, can affect pain
in OA. Lin et al.21 found a signiﬁcant reduction in OA pain
with enhancement of treatment for coexistant depression in OA
patients.
Our study carries the inherent strengths of the original LEAP
data. These include the ﬁrst weekly independent measurements of
pain andmental health in a cohort of OA patients to our knowledge.
Other strengths include a plausible time frame for a causal
relationship between predictor and outcome of approximately
1 week, convincing trends in the data that appear stable, and
a case-crossover analysis which demonstrates a persuasive relation
to pain ﬂares in a manner which eliminates questions of genetic,
experiential, and neuronal differences between subjects. Further-
more, the differences across groups in mental health in LEAP are
large. Nettles et al.36 state that “a change of more than 10 points [in
a normalized scale of the MHI-5] was considered a signiﬁcant
change in mood”; a change of 10 points in the Nettles paper
corresponds to a change of 2.5 points on the raw MHI-5 scale we
use in this paper, which is much smaller than the change values we
observed in the LEAP study.
There are also signiﬁcant limitations in our study. These include
combining hip and knee OA subjects into one cohort. Our most
signiﬁcant limitation, however, is intrinsic to the study of pain and
mental health in any setting: it is quite difﬁcult to address the
spectre of reverse causality in these data. It may be true, as we have
found, that mental health affects pain levels in OA. It seems intui-
tively true, however, that pain in OA affects mental health, and to
disentangle this relationship is daunting. For example, although we
have separated the independent variable from the outcome by 1
week in these analyses, it still may be the case that subjects have
a premonition of pain they will experience the next week which
could affect their mental health. Although we have tried to
establish the mental health variable as predictive in our analysis,Table III
MHI-5 and its relation to pain ﬂares (case-crossover analysis). Adjusted for medi-
cation use
MHI-5 quartile
range
N case
periods
N control
periods
Unadjusted
odds ratio
Adjusted
odds ratio
28e30 (ref) 77 143 1.00 1.00
26e27 68 89 1.18 1.19
23e25 89 86 2.05 1.95
13e22 102 95 2.01 2.11
P for trend 0.002 <0.001this does not negate the possibility that reverse causality plays
a signiﬁcant role in the results.
It may be that ultimately the question of causality is academic.
There may be an iterative process at work, with an ongoing stream
of OA pain and related worsened mental health that feeds back on
itself over time. Certainly the cross-sectional association we have
found is consistent with such a picture. It is worth considering
whether entering that process at any point with a therapeutic
intervention related to mental health will have the capability to
abort the circular pain process. The relationship of pain to mental
health may be mediated in part by a variety of factors, including
social isolation, sleep changes, and changes in physical activity. We
were not able to look at these questions given the information
collected in the LEAP study.
In conclusion, we have shown that worse or worsening mental
health precedes reporting of worse OA-related pain and OA pain
ﬂares. With the paucity of effective interventions for OA pain and
the toxicities of some in common use, mental health may represent
a new therapeutic target for OA pain, with potential signiﬁcant
opportunities for both patients and physicians.
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